Zydus Cadila's shares jumped over 4% to close at over ₹570 apiece on Friday. This was after the Drugs Controller General of India (DCGI) gave emergency approval for its anti-viral drug Pegylated Interferon alpha-2b, 'Virafin' for treating moderate COVID-19 infections in adult. The firm's MD Sharvil Patel said the drug will be available in the market in next few days.